An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Aplastic Anemia Clinical Trial

Official title:

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05333861
• Other study ID #: Hetrombopag-ITP/AA
• Status: Not yet recruiting
• Start date: May 1, 2022
• Est. completion date: May 1, 2026

Study information

• Verified date: April 2022
• Source: Wuhan Union Hospital, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to the knowledge base regarding the use of hetrombopag in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving hetrombopag for the treatment of ITP/AA

Description:

This is a multi-center, observational study in patients with ITP/AA designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to the knowledge base regarding the use of hetrombopag in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving hetrombopag for the treatment of ITP/AA The scope of the study is to collect both retrospective and prospective data. The main part of the study will be prospective collecting data on usage, effectiveness, safety and patient-reported outcomes whereas the retrospective part will consist of collection of information on previous treatments, reason for treatment switch and, if applicable, hetrombopag treatment prior to enrollment. The retrospective data collection will be based on the information available in the patient's medical records. Data will be collected for up to 12 months prior to hetrombopag treatment start. Prospective data will be collected at routine clinical visits throughout the study. Patients will be followed for 24 months and will be enrolled until their first scheduled visit after 24 months of enrollment, or until early termination, whichever occurs first.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1150
• Est. completion date: May 1, 2026
• Est. primary completion date: May 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• 1.Established and well documented ITP diagnosis
• 2.Patient is treated with, or at enrollment prescribed hetrombopag for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study.
• 3.Signed and dated informed consent provided by the patient before any study-related activities are undertaken
• 4.Willing and able to comply with protocol requirements

Exclusion Criteria:

• Enrollment in a concurrent clinical interventional study

Related Conditions & MeSH terms

• Anemia, Aplastic
• Aplastic Anemia
• Primary Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• hetrombopag
According to prescription

Locations

Country	Name	City	State
China	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China	Jiangsu Hengrui Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events	Information will be collected via reports from the Investigators based on the patient's medical records and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0	Data will be collected for all routine visits completed during the study period no more than 24 months.
Secondary	Number and proportion of patients achieving hematologic response after 3/6/12/24 months treatment	Laboratory measures of CBC will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts and other hematologic assessments will be based on local laboratory results.	Data will be collected for all routine visits completed during the study period which is no more than 24 months.
Secondary	The maximum continuous duration and total duration of response	Hematologic assessments will be based on local laboratory results	Data will be collected for all routine visits completed during the study period which is no more than 24 months.
Secondary	Number and proportion of patients requiring rescue medication.	Information will be collected via the patient's medical records.	Data will be collected for all routine visits completed during the study period which is no more than 24 months.
Secondary	Change from enrollment in the 36-Item Short Form Survey (SF-36)	SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting.	Data will be collected for all routine visits completed during the study period which is no more than 24 months.
Secondary	Change from enrollment in the use of concomitant ITP/AA medications throughout the study	Information will be collected via the patient's medical records.	Data will be collected for all routine visits completed during the study period which is no more than 24 months.
Secondary	Number and proportion of patients achieving a sustained remission off-treatment (SROT) after discontinuation of hetrombopag	The proportion of responders that were able to taper and discontinue hetrombopag maintaining the response during a period of observation of at least six months.	Data will be collected for all routine visits completed during the study period which is no more than 24 months.